Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 1900-1908, 2003; 10.1373/clinchem.2003.023481
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Poujol, S.
Right arrow Articles by Bressolle, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Poujol, S.
Right arrow Articles by Bressolle, F.
Related Collections
Right arrow Laboratory Management
Right arrow Clinical Immunology
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 2003;49:1900-1908.)
© 2003 American Association for Clinical Chemistry, Inc.

Automation and Analytical Techniques

Sensitive HPLC-Fluorescence Method for Irinotecan and Four Major Metabolites in Human Plasma and Saliva: Application to Pharmacokinetic Studies

Sylvain Poujol1, Frédéric Pinguet1, Françoise Malosse1, Cécile Astre1, Marc Ychou2, Stéphane Culine2 and Françoise Bressolle3,a

1 Oncopharmacology Department, Pharmacy Service, and
2 Department of Medicine, Val d’Aurelle Anticancer Centre, Parc Euromédecine, 34298 Montpellier, Cedex 5 France.

3 Clinical Pharmacokinetic Laboratory, Faculty of Pharmacy, 15 Avenue Ch. Flahault, University Montpellier I, 34093 Montpellier Cedex 5, France.

aAddress correspondence to this author at: Laboratoire de Pharmacocinétique Clinique, Faculté de Pharmacie, BP 14491, 34093 Montpellier Cedex 5, France. Fax 33-4-6754-8075; e-mail Fbressolle{at}aol.com.

Background: We developed gradient HPLC methods for quantification of the antimitotic drug irinotecan (CPT-11) and its four metabolites, SN-38, SN-38 G, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin (APC), and 7-ethyl-10-[4amino-1-piperidino]-carbonyloxycamptothecin (NPC), as the sum of the lactone and carboxylate forms, in human plasma and saliva. Camptothecin was used as internal standard.

Methods: The sample pretreatment involved protein precipitation with methanol–acetonitrile (50:50 by volume) followed by acidification with hydrochloric acid to convert the lactone ring-opened form into its lactone form, quantitatively. HPLC separation was performed on a Xterra RP18 column. The excitation wavelength was 370 nm, and the emission wavelength was set at 470 nm for the first 24 min and then at 534 nm for the next 4 min. The stabilities of irinotecan and its four metabolites in plasma, saliva, and acidic extracts were also investigated under various conditions.

Results: Assays were linear in the tested range of 0.5–1000 µg/L. For the five analytes, limits of quantification were 0.5 µg/L in both matrices. The interassay imprecision (as relative standard deviation) was 3.2–14% in plasma and 2.6–5.6% in saliva. Assay recoveries ranged from 92.8% to 111.2% for plasma and 100.1% to 104.1% for saliva. Mean extraction recovery from plasma or saliva was 90%.

Conclusion: The developed assay can be used to determine pharmacokinetic parameters for CPT-11, SN-38, SN-38 G, APC, and NPC in plasma and saliva from patients with metastatic colorectal cancer.




The following articles in journals at HighWire Press have cited this article:


Home page
 Molecular Cancer TherapeuticsHome page
Z. M. Prijovich, K.-C. Chen, and S. R. Roffler
Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy
Mol. Cancer Ther., April 1, 2009; 8(4): 940 - 946.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
D. Czock, F. M. Rasche, B. Boesler, M. Shipkova, and F. Keller
Irinotecan in Cancer Patients with End-Stage Renal Failure
Ann. Pharmacother., February 1, 2009; 43(2): 363 - 369.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Toffoli, E. Cecchin, G. Corona, A. Russo, A. Buonadonna, M. D'Andrea, L. M. Pasetto, S. Pessa, D. Errante, V. De Pangher, et al.
The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer
J. Clin. Oncol., July 1, 2006; 24(19): 3061 - 3068.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Cecchin, G. Corona, S. Masier, P. Biason, G. Cattarossi, S. Frustaci, A. Buonadonna, A. Colussi, and G. Toffoli
Carboxylesterase Isoform 2 mRNA Expression in Peripheral Blood Mononuclear Cells Is a Predictive Marker of the Irinotecan to SN38 Activation Step in Colorectal Cancer Patients
Clin. Cancer Res., October 1, 2005; 11(19): 6901 - 6907.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.